The Q(u)ALYfying Hand: Health Economics and Medicine in the Shaping of Swedish Markets for Subsidized Pharmaceuticals

Sjögren, Ebba; Helgesson, Claes-Fredrik

doi:10.1111/j.1467-954x.2007.00737.x

Cited by 40 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here we are inspired by studies that have used concepts and sensibilities from STS for studying the intertwinement of technologies and economical practices such as in social studies of finance (MacKenzie & Millo 2003;MacKenzie 2009) as well as more broadly in research on calculative practices and performativity of economics, on how calculative devices and economic theories shape markets and agencies (Callon & Muniesa 2005;Callon et al 2007;MacKenzie et al 2007;Sjögren & Helgesson 2007;Cochoy 2008;Skaerbaek & Tryggestad 2010).…”

Section: Values and Valuations As Topics In The Study Of Knowledge Prmentioning

confidence: 99%

Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials

Helgesson

Lee

Lindén

2015

Journal of Cultural Economy

Self Cite

View full text Add to dashboard Cite

This article examines the shifting conditions for biomedical knowledge production by studying trends in the design of biomedical experiments. The basic premise of the study is that the very act of establishing a research design entails a process involving a series of valuations where different values are evoked, ordered, and displaced. In focus is the articulation and ordering of what counts as central values in research design for two kinds of biomedical treatment trials, namely the traditional randomised controlled trial (RCT) and the emerging new form of biomarker trials used to assess biomarker/treatment combinations (BTTs). The empirical material consists of textbooks (RCTs) and journal articles (BTTs). We ask how these materials articulate the various scientific, medical, and economic values at play. Among the differences uncovered are a difference in relation to what counts as ethical in relation to prior knowledge, differences in the flexibility in design as well as the valuation of the risk for false positives and false negatives. More broadly, the study shows how textual accounts of different ways of producing knowledge are linked to partly different valuations of ethics, flexibility, and risk as part of establishing the research design of biomedical experiments. ARTICLE HISTORY

show abstract

Section: Values and Valuations As Topics In The Study Of Knowledge Prmentioning

confidence: 99%

Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials

Helgesson

Lee

Lindén

2015

Journal of Cultural Economy

Self Cite

View full text Add to dashboard Cite

show abstract

“…It makes up a form of 'currency' by which matters and entities that are usually perceived to be different becomes transported by a single metric. When introduced in policymaking, it performs new couplings between social and public values, and reconfigures the organizational framing to become more economic in kind (Moreira, 2013;Sjögren & Helgesson, 2007). ordering solution. 21 However, not market per se, but markets specifically constructed for welfare service such as healthcare markets.…”

mentioning

confidence: 99%

Valuation in Welfare Markets : The Rule Books, Whiteboards and Swivel Chairs of Care Choice Reform

Krafve¹

2015

View full text Add to dashboard Cite

“…The wide use and the implications of the QALY as a performative market device have already been recognised (Sjögren & Helgesson, 2007). Matas and Schnitzler assume that the QALY for transplants is the same as for dialysis, and thus calculate the long term opportunity cost of dialysis.…”

mentioning

confidence: 99%

On the Possibility of Organ Markets and the Performativity of Economics

Roscoe¹

2013

Journal of Cultural Economy

View full text Add to dashboard Cite

Callon's (1998) 'performativity thesis' encourages us to consider how the boundaries of the economy are negotiated. This paper explores one such discussion: the contributions of economics to the debates over the introduction of markets for transplant organs. The paper pays particular attention to the normative aspects of economic valuation. It examines the philosophical antecedents of economic contributions to the debate, notes the rhetorical and linguistic power of economic calculation and then focuses on three distinct sets of calculations concerning the value of a transplant kidney: a contingent valuation calculation, a risk-premia based calculation, and a cost-efficiency simulation. In each case, it shows that economic facts, once created, may travel freely through normative debates and claim moral force. The technical process of economic modelling is therefore seen to be a crucial aspect of the economisation of this area, and of economic performativity more generally.

show abstract

The Q(u)ALYfying Hand: Health Economics and Medicine in the Shaping of Swedish Markets for Subsidized Pharmaceuticals

Cited by 40 publications

References 19 publications

Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials

Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials

Valuation in Welfare Markets : The Rule Books, Whiteboards and Swivel Chairs of Care Choice Reform

On the Possibility of Organ Markets and the Performativity of Economics

Contact Info

Product

Resources

About